Assembly Biosciences (ASMB) Common Equity (2010 - 2026)

Assembly Biosciences' Common Equity history runs 17 years deep, the most recent figure standing at $198.6 million for Q1 2026.

• On a quarterly basis, Common Equity rose 631.99% year-over-year to $198.6 million in Q1 2026; TTM through Mar 2026 was $198.6 million, a 631.99% increase from a year earlier, with the FY2025 full-year figure at $206.8 million, up 519.78% from the prior year.
• Common Equity slipped to $198.6 million in Q1 2026 per ASMB's latest filing, from $206.8 million in the prior quarter.
• Across five years, Common Equity topped out at $206.8 million in Q4 2025 and bottomed at $18.1 million in Q2 2025.
• The 5-year median for Common Equity is $54.9 million (2023), against an average of $83.8 million.
• Across the five-year window, Common Equity slumped 59.27% in 2023 and surged 631.99% in 2026, its largest moves.
• Year by year, Common Equity stood at $82.7 million in 2022, then slumped by 50.28% to $41.1 million in 2023, then retreated by 18.83% to $33.4 million in 2024, then soared by 519.78% to $206.8 million in 2025, then decreased by 3.94% to $198.6 million in 2026.
• Per Business Quant, the three latest ASMB Common Equity figures stand at $198.6 million (Q1 2026), $206.8 million (Q4 2025), and $182.7 million (Q3 2025).